Harvard Medical School At Massachusetts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Why Seelos Therapeutics (SEEL) Stock Is Trading Higher Today - Seelos Therapeutics (NASDAQ:SEEL)

Seelos Therapeutics Inc (NASDAQ: SEEL) announced preclinical data from an in vivo study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in an aggressive Alzheimer's disease 

United statesHarvard medical school at massachusettsSeelos therapeutics incHarvard medical schoolMassachusetts general hospitalSeelos therapeutic partAcute suicidal ideationMajor depressive disorder

Seelos Therapeutics Provides Second Quarter 2023 Clinical Update

- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation .

United statesNew yorkAnthony marcianoMike moyerLos angelesLifesci advisorsHarvard medical school at massachusettsSociety for neuroscienceNasdaq hearings panelPrnewswire seelos therapeutics incSeelos therapeutics incAccess programNasdaq stock marketExchange commissionAmerican society of geneNational institute of neurological disorders

Cambridge, Mass , is offering residents $200 to get to know their neighbors

Residents of Cambridge, Massachusetts, can throw a block party on the city's dime.

Charles riverUnited statesUnited kingdomRobert waldingerIram farooqHarvard medical school at massachusettsEast coastStreet kitsHarvard medical schoolMassachusetts general hospitalGood life

Seelos Therapeutics Announces Mid-Year 2021 Business and Clinical Update

Seelos Therapeutics Announces Mid-Year 2021 Business and Clinical Update
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesAptar pharma bidoseAnthony marcianoAustralian patent officeVyera pharmaceuticalsHarvard medical school at massachusettsSeelos therapeutics incStrategic device partnershipExchange traded fundHorizons psychedelic stock index fundExchange commissionAptargroup incHead of corporate communicationsNational suicide prevention lifelineJapanese patent office

Seelos Therapeutics Announces Year End 2020 Business Update

Seelos Therapeutics Announces Year End 2020 Business Update -Highlights of Continued Execution of Plans for Multiple Clinical Programs and Upcoming Catalysts -Additions to the Clinical, Operational and Regulatory Teams News provided by Share this article Share this article NEW YORK, Jan. 6, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year end 2020 business update. This past year marked the most significant 12 months in Seelos Therapeutics history despite being an otherwise challenging year due to the COVID-19 pandemic. We completed our safety trial for the intranasal ketamine program and began opening centers for our pivotal trial for Acute Suicidal Ideation and Behavior in patients with major depressive disorder. The trehalose program s pivotal study in ALS was accepted into the HEALEY ALS Platform

New yorkUnited statesWarrenw wasiewskiManira rayamajhiKimberly farrandJessica kardishTim whitakerLucas pilipskiAnthony marcianoDavidm biondiJohns hopkins universityDickinson collegeHead of researchGeorge washington universityUniversity of north carolina at chapel hillSeelos team